Clinical-stage biopharmaceutical company DBV Technologies (Euronext Paris:DBV) (Nasdaq Capital Market:DBVT) on Friday announced a financing agreement of up to USD306.9m (EUR284.5m), including USD125.5m (EUR116.3m) upfront and up to USD181.4m (EUR168.2m) contingent on the full exercise of warrants.
These funds will support the preparation and submission of a Biologics License Application (BLA) for the Viaskin peanut patch, for the treatment of peanut allergy in children aged 4 to 7, and its potential US commercial launch. The financing will result in an immediate dilution of 22.4%, rising to 73.7% if all warrants are exercised.
The financing was led by MPM BioImpact, Adage Capital Management LP, Janus Henderson Investors, Vivo Capital and other healthcare-focused funds.
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial